Experience

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common…

Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with a Rule 144A offering by Novavax, Inc. of an aggregate principal amount of …

Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc. where Acorda will make a public tender offer in Finland and the…

Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…

Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering of 2,875,000 shares of common stock of Adamas Pharmaceuticals, Inc…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of Cempra, Inc. The net proceeds to Cempra were approximately $93.7…

Davis Polk advised the representatives of the initial purchasers on two Rule 144A/Regulation S offerings by Mylan N.V. of $500 million aggregate principal amount of its 3.000% senior notes…

Davis Polk advised Penumbra, Inc. on its SEC-registered initial public offering of 4,600,000 shares of common stock for an aggregate price to the public of approximately $138 million,…

Davis Polk advised the underwriters, in connection with an SEC-registered offering by Seattle Genetics, Inc. of 13,463,415 shares of common stock, which includes 1,756,097 shares of common…

Davis Polk advised the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.900% senior notes due 2020, $1.0 billion principal…